# A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors

Source: https://onco.cc/trials/nct07213609/  
OnCo record `nct07213609` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of GSK5460025 in colorectal cancer, run by GlaxoSmithKline, now recruiting.

## Summary

A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07213609 by GlaxoSmithKline, with 47 participants planned, started 2025-10-20 and due to reach its primary completion in 2028-09-28. Interventions recorded: GSK5460025.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07213609
- Phase: 1/2
- Setting: A Phase 1/2 Open-label, Multicenter Study of Oral GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors
- Sponsor: GlaxoSmithKline
- Enrolled: 47

## Sources

- ClinicalTrials.gov NCT07213609: https://clinicaltrials.gov/study/NCT07213609

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07213609.json